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Abstract: Targeting receptor systems by competitive inhibition is the objective of various
protein drugs in development and on the market. A variety of receptor systems also constitute
a degradation mechanism for ligand and drug via endocytosis and therefore influence the
microenvironment of the cell. A thorough understanding of the complex interplay between ligand
kinetics, drug pharmacokinetics, and the drug effect arising from the inhibition of the receptor
by competing with the natural ligand is largely missing. Based on a mathematical model of
the drug-ligand-receptor dynamics we show that receptor inhibition may lead to accumulation
of the natural ligand in the microenvironment of the cell, with counteracting impact on the
inhibitory effect of the drug. In the absence of receptor-independent ligand degradation, we
prove analytically that this counteracting effect cannot be eliminated by changing the structural
properties of the drug, like the affinity, nor by changing drug dosage. It is a structural property
of the type of receptor system under study that is due to the fact that inhibition influences the
ligand concentration in the microenvironment. The results suggest that the microenvironment
may have an influence on the success of drug treatment with competitive inhibitors, e.g., for
therapeutic proteins in cancer therapy.
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1. INTRODUCTION
Proteins drugs such as monoclonal antibodies, growth
factors and cytokines have been a major focus of research
and development activities in the pharmaceutical industry
over the past years (Meibohm, 2007). Their significant
therapeutic potential results from their ability to bind
with high affinity to specific targets such as receptors
or cell surface proteins. Receptor binding often results
in subsequent internalization and eventually degradation,
which for many protein drugs is an important route of
elimination (Meibohm, 2007).
Receptors are promising drug targets because they trans-
mit external signals across the cellular membrane, which
are processed by downstream signalling cascades and lead
to the cells’ functional responses (e.g., changes in gene
transcription). Alterations in the receptor’s ability to
transduce information can result in the development of
diseases. In cancer, for example, some of these alterations
result from mutations in the receptor that increase the
sensitivity of the cell to growth factors (Wells et al., 1990).
Normally, growth factors are tightly controlled. After re-
ceptor activation the growth factor molecule is cleared
from the environment by receptor mediated endocytosis
(RME). Local processes like autocrine and paracrine sig-
nalling as well as degradation of ligands by RME are likely
to be important in the microenvironment of target cells, in
particular, if the exchange with distant cells is impaired,
like it is observed in solid tumors.
In this article we study the blockage of receptor activation
by inhibitory drugs, and its interplay with the ligand con-
centration in the microenvironment of the cell. We focus on
receptor systems where the ligand is internalized by RME
after receptor activation. This is the case for a variety of
receptor families (Backer et al., 1991; Flores-Morales et al.,
2006; Hilton and Nicola, 1992), including the important
receptor tyrosine kinases activated by growth factors. Ex-
isting in silico studies of receptor systems focus on the
ligand-receptor interaction (e.g., (Shankaran et al., 2007,
2006)) or on the drug-receptor interaction (e.g., (Mager,
2006)). In contrast, our analysis is based on a mathemati-
cal model that describes the time-dependent interaction of
drug, ligand and the receptor system, yielding important
new insight.
2. MODEL DESCRIPTION
Our proposed model to study the inhibition of receptor
activation by therapeutic proteins is based on a well-
established ligand-receptor interaction model (Shankaran
et al., 2007, 2006; Lund et al., 1990; Wiley and Cunning-
ham, 1981). This canonical model was extended to also
account for the drug-receptor interaction, which has been
studied in pharmacokinetics based on target-mediated
drug-disposition models (Mager, 2006). Our model is
shown in Fig. 1.
In the model, both ligand L and drug D are present in
the extracellular space (with volume V ). The ligand enters
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Fig. 1. Natural ligand and inhibitor drug competing for
receptor binding.
the extracellular space at rate kL, and is cleared with
rate constant kdegL. The drug enters the extra-cellular
space at rate fdose(t). The free membrane receptor R is
produced at rate kR and internalized with the rate con-
stant kdegR. Both ligand and drug reversibly bind to free
receptors R with association rate constant konL and konD,
respectively, and a dissociation rate constant koffL and
koffD, respectively. The resulting ligand-receptor complex
RL and drug-receptor complex RD are internalized by
forming an endosome with the rate constant kdegRL and
kdegRD, respectively.
Based on the law of mass action, the rates of change for
the molecular species are given by the following system of
ordinary differential equations (ODEs):
dL
dt
=
kL
V Na
−
konL
V Na
RL+
koffL
V Na
RL − kdegLL,
dD
dt
= fdose(t)−
konD
V Na
RD +
koffD
V Na
RD,
dR
dt
= kR − konLRL− konCRD + koffLRL
+ koffDRD − kdegRR, (1)
dRL
dt
= konLRL− koffLRL − kdegRLRL,
dRD
dt
= konDRD − koffDRD − kdegRDRD.
The species L and R are expressed in [M]; R, RL and
RD are in units [# molecules]. Division by the product of
Avogadro’s constant Na and volume V ensures conversion
from units [# molecules] to [M]. The non-negative drug
dosing rate is given by fdose(t) = f(t) ·Dose, with∫
∞
0
f(t) dt = 1. (2)
Different dosing regimes can be modeled by choosing f(t)
appropriately. For example, a bolus-dose at time t = 0 is
represented by choosing f as a delta-distribution at t = 0.
Prior to any drug administration, the system is assumed
to be in steady state, resulting in some number of active
receptor RL = R
∗
L. The effect of the drug results from the
inhibition of receptor activation, i.e., from the change in
the number of active receptor RL(t) over time. Since this
effect depends on the dosing function fdose(t), the problem
can be interpreted as a control problem (Franklin et al.,
2002) where fdose(t) acts as an external input that has to
be designed to push the output RL(t) below its steady-
state value.
For simulation purposes only, we used experimentally
determined parameter values for the epidermal growth
factor receptor (EGFR), see Table 1, and assumed that the
drug-related parameters were identical to the parameters
of the natural ligand.
Table 1. Parameter values for the EGF recep-
tor system. a Hendriks et al. (2005); b Resat
et al. (2003)
Constant Value Unit Constant Value Unit
konL 2.47
a nM konD 2.47 nM
koffL 0.24
a (1/min) koffD 0.24 (1/min)
kdegR 0.02
b (1/min) kdegL (see Fig) (1/min)
kdegRL 0.15
b (1/min) kdegRD 0.15 (1/min)
Since prior to drug application, the receptor system was
assumed to be in steady-state, we used steady-state values
of 2 · 105 receptors per cell (EGFR expression level in
human mammary epithelial cells (Shankaran et al., 2007)
and a ligand concentration of 10 ng/ml (Goldstein et al.,
1995)) to determine the parameters kL and kR (with
molecular weight 133.07 kD for EGF). The total drug dose
was chosen as Dose =10 µg/ml (Goldstein et al., 1995).
The volume V was 4 ·10−10 l/cell (Shankaran et al., 2007).
3. RESPONSE TO DRUG ADMINISTRATION
Single bolus dose. In the following we consider the
response of the receptor system to a single bolus dose of
the inhibitor. Figure 2 shows the time course of the drug
concentration in the microenvironment and the resulting
number of active receptors RL for different values of the
ligand clearance rate kdegL. Following the bolus dose at
time t = 0, the number of activated receptors drops rapidly
to a much lower level. Inhibition of active receptors is due
to the competition for free receptors between the natural
ligand and the drug. Since binding to receptor implies
internalization and degradation, the drug concentration
decreases over time such that eventually the number of
active receptors recovers to its unperturbed steady-state
level (black dashed line).
We identify two phases in Fig. 2: In a first phase the
number of active receptors decays below its steady-state
level, resulting in an inhibition of the receptor system;
in a second phase, however, the active receptors are
above their steady-state, resulting in an induction of the
receptor system. The extent of inhibition and induction
depends on the clearance rate constant kdegL. For the
highest clearance rate constant kdegL = 0.01/min, the
induction phase is almost absent, whereas for kdegL = 0
the induction phase is the highest. The inset in Fig. 2
shows the increase and decline of the ligand concentration
in the microenvironment of the cell. Ligand accumulation
is a consequence of the drug binding to the receptor such
that less ligand is bound to the receptor and subsequently
degraded. For low values of kdegL, the extracellular ligand
accumulates considerably, while for high values of kdegL it
is cleared by the receptor-independent route.
To further understand the relation between inhibition and
induction, it is useful to quantify the drug effect in a
precise way. As a measure of the drug effect we consider
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Fig. 2. Dynamic response of the number of active receptors
(with circle markers) and drug concentration (without
markers) after bolus dose for different ligand clear-
ance rates kdegL. Inset: Ligand accumulation in the
microenvironment of the cell over time.
E =
∫
∞
0
(
R∗L −RL(t)
)
.dt, (3)
Thus, E measures the net inhibition as the sum of the
inhibition and induction. Fig. 2 shows that small values of
kdegL increase the induction phase and decrease the inhi-
bition phase, implying a lower net inhibition according to
eq. (3). Moreover, in the case of kdegL = 0 we numerically
observe a zero net inhibition (E = 0), which suggests that
ligand accumulation totally counteracts the drug effect.
Multiple bolus dose. To prevent the induction phase,
one dosing strategy could be to administer a follow-up dose
each before the induction phase starts. As can be inferred
from Fig. 3, this is a feasible strategy, but possibly at the
cost of a larger induction phase after the final dose due to
a longer ligand accumulation phase (see inset in Fig. 3).
For kdegL = 0, numerical computations show a zero net
inhibition as in the previous case.
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Fig. 3. Dynamic response of the number of activated re-
ceptors (solid line with circles) and drug concentration
(solid line) after multiple bolus doses for kdegL = 0.
Inset: Ligand accumulation in the microenvironment
of the cell over time.
4. THEORETICAL ANALYSIS OF NET INHIBITION
In the following we analytically show that in the limiting
case when kdegL = 0, the net inhibition vanishes. There-
fore, in this scenario the extent of ligand accumulation and
the resulting induction phase do not depend on the model
parameters, which suggests that it is a structural property
of the studied receptor system.
We assume that the unique steady state L∗, D∗, R∗, R∗L
and R∗D is exponentially stable, which for any realistic
scenario is trivially satisfied. This guarantees that the net
effect E is well-defined. It is convenient rewrite the system
of ODEs (1) in terms of the deviations of the species
from their steady-state values. We define these incremental
variables as
L¯(t) = L∗ − L(t), R¯D = R
∗
D −RD(t),
R¯(t) = R∗ −R(t), R¯L = R
∗
L − RL(t),
D¯(t) = D∗ −D(t).
The resulting system of ODEs in terms of the incremental
state vector
x¯(t) =
[
L¯(t) D¯(t) R¯(t) R¯L(t) R¯D(t)
]T
is the given by
d x¯
dt
= Ax¯(t) + BRLR¯(t)L¯(t) + BRDR¯(t)D¯(t)−Bf(t),
(4)
with x¯(0) = [0 −D(0) 0 0 0]
T
, and where A is the
Jacobian of the right hand side of (1) evaluated at the
steady state (given in eq. (5)). The vectors BRL, BRD
and B are given by
BRL =
[
konL
V Na
0 konL −konL 0
]T
,
BRD =
[
0
konD
V Na
konD 0 −konD
]T
,
B = [0 1 0 0 0]
T
.
Integration of (4) from t = 0 to infinity gives
x¯(∞)− x¯(0) = A
∫
∞
0
x¯(t) dt+ BRL
∫
∞
0
R¯(t)L¯(t) dt
+ BRD
∫
∞
0
R¯(t)D¯(t) dt−B
∫
∞
0
f(t) dt.
(6)
The stability of the system implies x¯(∞) = 0, and using
the initial condition yields∫
∞
0
x¯(t) dt = A−1B ·Dose
−A
−1
BRL
∫
∞
0
R¯(t)L¯(t) dt
−A
−1
BRD
∫
∞
0
R¯(t)D¯(t) dt. (7)
We notice that E =
∫
∞
0
[x¯(t)]
4
dt and moreover,[
A
−1
B
]
4
=
[
A
−1
BRL
]
4
=
[
A
−1
BRD
]
4
= 0, (8)
which finally implies the claimed result E = 0. Hence,
in absence of receptor-independent ligand clearance, the
inhibition and subsequent induction phase are identical,
resulting in a zero net inhibition. Since this phenomenon is
A =


−
konLR
∗
V Na
0 −
konLL
∗
V Na
koffL
V Na
0
0 −
konDR
∗
V Na
− kdegD 0 0
koffD
V Na
−konLR
∗
−konDR
∗
−konLL
∗
− kdegR koffL koffD
konLR
∗ 0 konLL
∗
−koffL − kdegRL 0
0 konDR
∗ 0 0 −koffD − kdegRD


. (5)
independent of any drug-specific parameters and receptor-
system parameters, it is suggested that it is a structural
feature of the considered receptor class.
5. DISCUSSION AND CONCLUSION
Our analysis suggests that the effect of receptor antag-
onistic drugs could be negatively affected by the ligand
accumulation in the microenvironment of the target cells.
The results show that the response of the receptor sys-
tem to the drug might have two counteracting phases:
An initial inhibitory phase and a second inductive phase.
The latter is due to extracellular accumulation of the
ligand, which is larger for environments where receptor-
independent ligand clearance is slow. In such situations
the inhibitor only postpones the activation, until the local
concentration of the drug has sufficiently declined, act-
ing as a memory of the lost activation resulting from
the inhibition of the system. In the limiting (theoretical
case) when there is no receptor-independent ligand clear-
ance, the induction of active receptors totally offsets the
inhibitory response and renders a nil total drug effect.
Importantly, the counteracting effect cannot be reduced
by altering the affinity of the drug or the dosing scheme,
since it is independent from any drug related parameters;
it is a structural property of the considered receptor class.
The dosing function can be regarded as an external input
signal that is applied to the receptor system to control
its activation. The phenomenon of counteracting ligand
accumulation constitutes a “fundamental limitation” in
the inhibition of the receptor system, which resembles
those that typically arise in Control Engineering (Seron
et al., 1997). The study of fundamental limitations is an
extensive field of research in Control Engineering (Franklin
et al., 2002) that addresses the question how the structure
of the system limits certain characteristics of every possible
response to a class of inputs. Our analysis suggests that
this kind of limitations can also play an important role in
the design of dosing regimes.
It is known that the microenvironment of cells in solid
tumors can have a crucial influence on the success of
radiotherapy (Vaupel, 2004). Our analysis suggests that
the microenvironment may also influence the treatment
of cancer with therapeutic proteins used as receptor in-
hibitors.
An analysis of the implications for in vitro as well as in
vivo situations, is currently in preparation.
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